2021-01-03,"b'*FINAL REMINDER* [ Daily Study *VIDEO* ] "" 2021? PLEASE - Let\'s REDO 2020!!! ""          https://t.co/A0vunHEd3X   $MRNA, $REPL, $NSTG, $RGEN, $TCRR, $CRSP, $HALO, $BCLI, $ADPT, $NK, $LCTX, $VCEL, $TBIO, $BEAM, $IDRA, $FENC, $CGEN, $IOVA, $TCON, $ARGX, $XLRN, $BVXV, $APTO, $CLLS,'"
2021-01-03,b'NEWS #ARGENXSE ( $ARGX )  : https://t.co/hXBxuJED17 #Biotechnologie #StockMarket #Bourse'
2020-12-31,b'$CVX CEO Release Details of Pending Merger With Unnamed Nasdaq Traded Stock Following Talks In NYC\nhttps://t.co/Mv3xmUJu9A\n\n$SARA $PDT $CRNCY $TPGE $ATGN $ASAE $ARTX $ARTH $ARR $ARMO $ARLZ $ARGX'
2020-12-29,b'RT @BertrandBio: More on $ARGX change of plans to introduce the SC-ENHANZE efgartigimod in ITP. Prev. plans included a trial with IV induct\xe2\x80\xa6'
2020-12-29,b'RT @BertrandBio: More on $ARGX change of plans to introduce the SC-ENHANZE efgartigimod in ITP. Prev. plans included a trial with IV induct\xe2\x80\xa6'
2020-12-29,"b""More on $ARGX change of plans to introduce the SC-ENHANZE efgartigimod in ITP. Prev. plans included a trial with IV induction+SC maintenance, now it seems they'll just do a new trial (ADVANCE SC) with SC-ENHANZE efgar for both induction &amp; maintenance.\nhttps://t.co/hIRPddoSmv"""
2020-12-29,b'$CVX CEO Release Details of Pending Merger With Unnamed Nasdaq Traded Stock Following Talks In NYC\nhttps://t.co/Mv3xmUJu9A\n\n$SARA $PDT $CRNCY $TPGE $ATGN $ASAE $ARTX $ARTH $ARR $ARMO $ARLZ $ARGX'
2020-12-28,"b'RT @portefeuillefun: Sold 0.05k $ARGX at $301.01, now 0.25k #vssporte shares.'"
2020-12-28,"b'Sold 0.05k $ARGX at $301.01, now 0.25k #vssporte shares.'"
2020-12-28,b'$STSA to take a decision on ratifying forward split for implementation next quarter\nhttps://t.co/Mv3xmUJu9A\n\n$ASAE $ARTX $ARTH $ARR $ARMO $ARLZ $ARGX $ARES $ARCS $ARCH $ARCB $WSML $WRPSF'
2020-12-27,b'RT @semodough: Few other bull cases from MS. $ARGX   626. $SRPT 470  $MRNA 323   $BPMC 223.    $KPTI 68.  I be happy with base case 32. \xf0\x9f\x98\x83.'
2020-12-27,b'RT @semodough: Few other bull cases from MS. $ARGX   626. $SRPT 470  $MRNA 323   $BPMC 223.    $KPTI 68.  I be happy with base case 32. \xf0\x9f\x98\x83.'
2020-12-27,b'RT @semodough: Few other bull cases from MS. $ARGX   626. $SRPT 470  $MRNA 323   $BPMC 223.    $KPTI 68.  I be happy with base case 32. \xf0\x9f\x98\x83.'
2020-12-27,b'RT @semodough: Few other bull cases from MS. $ARGX   626. $SRPT 470  $MRNA 323   $BPMC 223.    $KPTI 68.  I be happy with base case 32. \xf0\x9f\x98\x83.'
2020-12-27,b'RT @semodough: Few other bull cases from MS. $ARGX   626. $SRPT 470  $MRNA 323   $BPMC 223.    $KPTI 68.  I be happy with base case 32. \xf0\x9f\x98\x83.'
2020-12-27,b'RT @semodough: Few other bull cases from MS. $ARGX   626. $SRPT 470  $MRNA 323   $BPMC 223.    $KPTI 68.  I be happy with base case 32. \xf0\x9f\x98\x83.'
2020-12-27,b'RT @semodough: Few other bull cases from MS. $ARGX   626. $SRPT 470  $MRNA 323   $BPMC 223.    $KPTI 68.  I be happy with base case 32. \xf0\x9f\x98\x83.'
2020-12-27,b'RT @semodough: Few other bull cases from MS. $ARGX   626. $SRPT 470  $MRNA 323   $BPMC 223.    $KPTI 68.  I be happy with base case 32. \xf0\x9f\x98\x83.'
2020-12-27,b'RT @semodough: Few other bull cases from MS. $ARGX   626. $SRPT 470  $MRNA 323   $BPMC 223.    $KPTI 68.  I be happy with base case 32. \xf0\x9f\x98\x83.'
2020-12-27,b'Few other bull cases from MS. $ARGX   626. $SRPT 470  $MRNA 323   $BPMC 223.    $KPTI 68.  I be happy with base case 32. \xf0\x9f\x98\x83.'
2021-01-07,"b'Next generation biotech platform leader:\n\n5)New Cell therapy: $FATE, $ALLO, $ALLO, $AFMD, $TCRR\n6)Antibody engineering: $SGEN, $RGEN, $GMAB,$YMAB, $ARGX $ZYME, $BCYC, $XNCR, $MGNX\n7) Kinase Inhibitor: $MRTX, $TPTX, $DCPH, $RLAY, $PRLD; $RVMD; $BDTX; $PMVP;$SDGR'"
2021-01-07,"b'Bought 0.25k $ARGX at $280.00, now 0.5k #vssporte shares.'"
2021-01-07,b'$VNE -1.7% (updates outlook)  \n\n$AR -1.1% (prices 31.4 million shares of its common stock at $6.35/share to certain holders of its 4.25% Convertible Senior Notes due 2026) \n\n$ARGX -1.1% (ZLAB and ARGX announce collaboration for efgartigimod in Greater China)'
2021-01-07,b'$ARGX\nARGX Target Raised by JMP Securities with price target $271.00 \xe2\x9e\x9d $307.00 and rating Outperform\nSource:https://t.co/cLuXiVHuP1\n\n$ATUS\nATUS Initiated by Evercore ISI  and rating Outperform\nSource:https://www.mark... https://t.co/xV3KnLNhrz'
2021-01-07,"b""RT @bradloncar: $ARGX and $ZLAB collaboration for Efgartigimod in China. argenx is taking $75M in Zai Lab stock for the upfront. I've been\xe2\x80\xa6"""
2021-01-07,b'Argenx price target raised to $293 from $283 at Wedbush\n$ARGX $ZLAB'
2021-01-07,b'Argenx price target raised to $272 from $249 at Wells Fargo\n$ARGX'
2021-01-07,"b'RT @kevinjaybe: $ARGX JPM Sec maintains Mkt Outperform, PT raised from 270 to 307'"
2021-01-07,b'RT @ResearchPool: $ARGX #Argenx S.E Enters Collab with Zai Lab: [...] https://t.co/WqpcYygncy #equity #stocks https://t.co/Pmz1DUnERO'
2021-01-07,b'$ARGX #Argenx S.E Enters Collab with Zai Lab: [...] https://t.co/WqpcYygncy #equity #stocks https://t.co/Pmz1DUnERO'
2021-01-07,"b'RT @kevinjaybe: $ARGX JPM Sec maintains Mkt Outperform, PT raised from 270 to 307'"
2021-01-07,b'Argenx price target raised to $307 from $271 at JMP Securities\n$ARGX'
2021-01-07,"b'$ARGX JPM Sec maintains Mkt Outperform, PT raised from 270 to 307'"
2021-01-07,b'We have collaborated with @argenxglobal to develop and commercialize #efgartigimod for patients living with severe #autoimmune diseases in Greater China.\n\nRead more: https://t.co/0P70BLnVSS\n\n$ZLAB #ZaiLab #ZLAB $ARGX https://t.co/j1WWxFDFBH'
2021-01-07,b'RT @JohnCendpts: EXCLUSIVE: Zai Lab\xe2\x80\x99s Samantha Du scoops up China rights to an autoimmune drug with a hefty $175M licensing deal \xe2\x80\x94 heavily\xe2\x80\xa6'
2021-01-07,"b""RT @bradloncar: $ARGX and $ZLAB collaboration for Efgartigimod in China. argenx is taking $75M in Zai Lab stock for the upfront. I've been\xe2\x80\xa6"""
2021-01-06,b'$ARGX: argenx and Zai Lab announce license agreement for the development of efgartigimod in Greater China https://t.co/yD8BT4ZIOl'
2021-01-06,"b""RT @bradloncar: $ARGX and $ZLAB collaboration for Efgartigimod in China. argenx is taking $75M in Zai Lab stock for the upfront. I've been\xe2\x80\xa6"""
2021-01-06,b'RT @BertrandBio: The upfront for $ARGX is not in cash but in newly issued Zai Lab shares. Btw this is the chart of Zai lab stock...\n\nAn ori\xe2\x80\xa6'
2021-01-06,"b'@adar170 According to my calculation, the premium matches the dilution. Minimal impact for $ARGX and strictly neutral for Zai Lab shareholders.'"
2021-01-06,b'RT @BertrandBio: The upfront for $ARGX is not in cash but in newly issued Zai Lab shares. Btw this is the chart of Zai lab stock...\n\nAn ori\xe2\x80\xa6'
2021-01-06,"b'568,182 newly issued Zai Lab shares calculated at a price of $132.00 per share for $ARGX'"
2021-01-06,"b""The upfront for $ARGX is not in cash but in newly issued Zai Lab shares. Btw this is the chart of Zai lab stock...\n\nAn original point: the licensing is for Greater China but the PR says there's a 25m$ milestone payment on... the US approval of efgartigimod (and not CN approval). https://t.co/Muq7QWdOPY"""
2021-01-06,b'RT @MSollender: $ARGX $ZLAB argenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China\n\nARGX to receive $75m upf\xe2\x80\xa6'
2021-01-06,b'RT @MSollender: $ARGX $ZLAB argenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China\n\nARGX to receive $75m upf\xe2\x80\xa6'
2021-01-06,b'RT @MSollender: $ARGX $ZLAB argenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China\n\nARGX to receive $75m upf\xe2\x80\xa6'
2021-01-06,"b""RT @bradloncar: $ARGX and $ZLAB collaboration for Efgartigimod in China. argenx is taking $75M in Zai Lab stock for the upfront. I've been\xe2\x80\xa6"""
2021-01-06,b'RT @MSollender: $ARGX $ZLAB argenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China\n\nARGX to receive $75m upf\xe2\x80\xa6'
2021-01-06,b'A Form 6-K  filing has been made with the SEC:  $ARGX ARGENX SE  https://t.co/qGDWRUl9Cr'
2021-01-06,"b""RT @bradloncar: $ARGX and $ZLAB collaboration for Efgartigimod in China. argenx is taking $75M in Zai Lab stock for the upfront. I've been\xe2\x80\xa6"""
2021-01-06,b'RT @JohnCendpts: EXCLUSIVE: Zai Lab\xe2\x80\x99s Samantha Du scoops up China rights to an autoimmune drug with a hefty $175M licensing deal \xe2\x80\x94 heavily\xe2\x80\xa6'
2021-01-06,b'$ARGX NEW ARTICLE : argenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China https://t.co/20tP8EUV0f Get all the latest $ARGX related news here : https://t.co/SSEi60RFdK https://t.co/Syb8mvoZP8'
2021-01-06,b'RT @MSollender: $ARGX $ZLAB argenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China\n\nARGX to receive $75m upf\xe2\x80\xa6'
2021-01-06,"b""$ARGX and $ZLAB collaboration for Efgartigimod in China. argenx is taking $75M in Zai Lab stock for the upfront. I've been telling U.S. companies they should do this."""
2021-01-06,b'$ARGX $ZLAB argenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China\n\nARGX to receive $75m upfront in Zai Lab equity at $132.00/sh; $100m in milestones\n\nhttps://t.co/hZseL3jloY'
2021-01-06,b'$ARGX and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China \n\nargenx to receive $75 million in upfront Zai Lab equity and $100 million in near-term milestone and other payments'
2021-01-06,"b'$ARGX [15s. delayed]: Issued Press Release on January 06, 16:01:00: argenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China https://t.co/o9ptMLUl7e'"
2021-01-06,b'EXCLUSIVE: Zai Lab\xe2\x80\x99s Samantha Du scoops up China rights to an autoimmune drug with a hefty $175M licensing deal \xe2\x80\x94 heavily fronted with cash and stock\n$ARGX $ZLAB\nhttps://t.co/0j0sYnCYJc'
2021-01-06,b'RT @Zypprr: Nice overview of EU biotech performance 2020 $ALBPS $IVA $VLA $KDS $ARGX $GMAB $ACPH $MITRA $PHARM $MOR $BOTHE $CYAD $GLPG #Bio\xe2\x80\xa6'
2021-01-06,b'RT @askwarrenbuffet: $BLDV BOD to advance merger talks following straw poll of investors who approve the move\nhttps://t.co/Mv3xmUJu9A\n\n$SAR\xe2\x80\xa6'
2021-01-06,b'Optimus v4\n2021-01-06 09:52 ET. *Closed/Sold:\n$ARGX at $280.74 for 1.47 profit (0.52%). argenx SE ADS (CORP).\nTrade Id: 63643603403033490.\nStats: https://t.co/oAX4hq6SAg'
2021-01-06,b'Optimus v4\n2021-01-06 09:36 ET. Bought/Opened:\n$ARGX at $279.14. \nargenx SE ADS (CORP).\nWin Chance: 65%. Avg Win: 5%. Avg Loss: 5.84%. Avg Hold: 8d.\nTrade Id: 63643603403033490.\nStats: https://t.co/oAX4hq6SAg'
